Monitoring of patients with prostate cancer after external radiotherapy

02/2021

MUDr. Petra Holubová, Ph.D.¹; doc. MUDr. Martin Doležel, Ph.D.^1,2,3; MUDr. Igor Hartmann, Ph.D.^2,4

¹ Onkologická klinika FN Olomouc

² Lékařská fakulta Univerzity Palackého, Olomouc

³ 1. lékařská fakulta Univerzity Karlovy v Praze

⁴ Urologická klinika FN Olomouc

SUMMARY

Serial evaluation of serum prostate-specific antigen is the mainstay of surveillance testing in men who have undergone definitive radiotherapy for localized prostate cancer. Based on the National Comprehensive Cancer Network guidelines serum prostate-specific antigen should be monitored every 6 to 12 months for the first five years and annually thereafter. There were created several nomograms to estimate a patienťs probability of long-term cure after radical local treatment using pathologic stage as a surrogate end point. Positron emission tomography using choline ¹⁸F-ftuciclovine and ⁶⁸Ga-labelled prostate-specific membrane antigen are an emerging radiological techniques developed to improve the characterization of relapsed prostate cancer. We can use several accepted toxicity grading scales for quantification of degree of damage of organs at risk (RTOG, FC-LENT SOMA, Common Terminology Criteria for Adverse Events).

Key words

radiotherapy, prostate cancer, toxicity, follow-up